Table 1.

Descriptive characteristics of the study group: patients transplanted for Budd-Chiari syndrome (BCS), mean ± SD or n (%).

Patient Characteristics
n	46
Female	32 (70%)
Male	14 (30%)
Age at transplantation, years	37 ± 11
Median (range)	36 (15–66)
Underlying disease
Myeloproliferative syndrome	22 (48%)
Genetic thrombophilia	11 (24%)
Anti-body mediated thrombophilia	5 (11%)
Not determined	8 (17%)
Known mutations
Factor V Leiden	7 (15%)
Janus Kinase 2	5 (11%)
Protein C deficiency	1 (2%)
Anti-body mediated thrombophilia
Antiphospholipid syndrome	4 (9%)
Heparin induced thrombopenia	1 (2%)
Cytoreductive therapy in MPS * patients (n = 22) post LT ¥
Hydroxycarbamide	12 (55%)
Anagrelide	3 (14%)
Hydroxycarbamide + anagrelide	2 (9%)
No cytoreductive therapy	5 (23%)
Post-transplant anti-coagulation
Anti-vitamin K	35 (76%)
Anti-vitamin K + acetylsalicylic acid	5 (11%)
No anticoagulation therapy	2 (4%)
Not available	4 (9%)
Immunosuppression
Calcineurin inhibitor	27 (59%)
Calcineurin inhibitor + antimetabolite	16 (35%)
Calcineurin inhibitor + prednisone	1 (2%)
Antimetabolite	1 (2%)
Not available	1 (2%)
Re-transplantation	11 (24%)
Initial non-functioning	4 (9%)
Recurrent Budd Chiari syndrome	3 (7%)
Arteria hepatica occlusion	2 (4%)
Chronic rejection	1 (2%)
Sinusoidal obstruction syndrome (SOS)	1 (2%)
Rejection episodes	9

* MPS = myeloproliferative syndrome, ^¥ LT = liver transplantation.